Naeem K Patil Selected Research

monophosphoryl lipid A

1/2020	The Metabolic Basis of Immune Dysfunction Following Sepsis and Trauma.
1/2020	Monophosphoryl Lipid a Attenuates Multiorgan Dysfunction During Post-Burn Pseudomonas Aeruginosa Pneumonia in Sheep.
11/2019	Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens.
1/2018	The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism.
4/2016	Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naeem K Patil Research Topics

Disease

11	Infections 12/2021 - 01/2016
11	Sepsis (Septicemia) 01/2020 - 11/2013
5	Burns 01/2020 - 01/2016
3	Wounds and Injuries (Trauma) 01/2017 - 01/2016
2	Pseudomonas Infections 12/2021 - 04/2016
2	Septic Shock (Toxic Shock Syndrome) 12/2019 - 01/2017
2	Critical Illness (Critically Ill) 12/2019 - 01/2018
2	Bacterial Infections (Bacterial Infection) 11/2019 - 01/2018
1	Pneumonia (Pneumonitis) 01/2020
1	Communicable Diseases (Infectious Diseases) 12/2019
1	Staphylococcal Infections 11/2019
1	Inflammation (Inflammations) 01/2019
1	Neoplasms (Cancer) 12/2017
1	Hypothermia 01/2017
1	Shock 01/2017
1	Wound Infection (Wound Infections) 01/2016
1	Cross Infection (Nosocomial Infection) 01/2016
1	Acute Kidney Injury (Acute Renal Failure) 01/2015
1	Mitochondrial Diseases (Mitochondrial Disease) 04/2014

Drug/Important Bio-Agent (IBA)

5	monophosphoryl lipid AIBA 01/2020 - 04/2016
3	LigandsIBA 01/2020 - 01/2017
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2016
3	CytokinesIBA 11/2019 - 01/2016
3	Interleukin-15 (Interleukin 15)IBA 12/2017 - 01/2016
2	Immunologic Factors (Immunomodulators)IBA 12/2021 - 01/2016
2	GlucansIBA 12/2021 - 01/2020
2	Toll-Like Receptor 4IBA 12/2019 - 11/2019
2	SolutionsIBA 11/2019 - 12/2017
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020
1	Toll-Like Receptor AgonistsIBA 01/2020
1	Pattern Recognition ReceptorsIBA 01/2020
1	Peptidoglycan (Murein)IBA 01/2020
1	Ringer's LactateIBA 11/2019
1	DisaccharidesIBA 11/2019
1	ceritinibIBA 11/2019
1	itaconic acidIBA 01/2019
1	FumaratesIBA 01/2019
1	Succinic Acid (Succinate)IBA 01/2019
1	Citric Acid (Citrate)FDA LinkGeneric 01/2019
1	InterferonsIBA 01/2018
1	InterleukinsIBA 12/2017
1	Immune Checkpoint ProteinsIBA 11/2017
1	flt3 ligand protein (flt3 ligand)IBA 01/2017
1	Immunoglobulin G (IgG)IBA 01/2017
1	Tyrosine (L-Tyrosine)FDA Link 01/2017
1	EndotoxinsIBA 01/2017
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2016
1	Sphingosine-1-Phosphate ReceptorsIBA 01/2015
1	Superoxides (Superoxide)IBA 04/2014
1	TEMPOIBA 04/2014
1	AntioxidantsIBA 04/2014
1	Superoxide DismutaseIBA 04/2014
1	Phosphodiesterase 4 InhibitorsIBA 11/2013
1	RolipramIBA 11/2013
1	Oxidants (Oxidizing Agents)IBA 11/2013

Therapy/Procedure

5	Therapeutics 01/2020 - 01/2015
5	Punctures 01/2017 - 11/2013
5	Ligation 01/2017 - 11/2013
4	Immunotherapy 01/2020 - 01/2016
1	Critical Care (Surgical Intensive Care) 01/2020
1	Anesthesia and Analgesia 01/2020
1	Induced Hypothermia 11/2019
1	Resuscitation 01/2016
1	Treatment Delay 11/2013